Hologic (HOLX) Q1 a Small Step Toward Rebuilding Credibility, Needham & Company Says

February 4, 2014 6:52 AM

Needham & Company analyst Mike Matson reiterated a Buy rating and $26 price target on Hologic (NASDAQ: HOLX) following solid ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found